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Abstract
Background: According to epidemiological studies, impaired glucose tolerance (IGT) is, in
common with diabetes, related to an increased risk of cardiovascular disease, including heart
failure (HF). Diastolic left ventricular function is one of the indices of HF severity, and
a restrictive filling pattern is related to increased mortality and a need for heart transplanta-
tion. The aim of the study was to evaluate left ventricular diastolic function in patients with
IGT and HF due to left ventricular systolic dysfunction.
Material and methods: In 61 patients with HF and left ventricular ejection fraction (LVEF)
< 45%, of mean age 50.5 ± 8.0 years, echocardiography with Doppler measurement of
diastolic function parameters and oral glucose tolerance test (OGTT) were performed. Restric-
tive filling pattern (RFP) was diagnosed with E/A > 2 or between 1 and 2 and DTE £ 130 ms.
Results: IGT was diagnosed in 25 patients and normal glucose tolerance (NGT) in
36 patients. There were no significant differences in baseline clinical characteristics and
LVEF between the two groups. In patients with IGT RFP was significantly more frequent
(60 vs. 33%; p = 0.039) and the patients were in a higher NYHA class than those with NGT.
In a multivariate regression analysis 2-h glucose level during OGTT was a significant predic-
tor of E/A ratio independent of NYHA class, diuretic dose and LVEF.
Conclusion: Diastolic dysfunction and functional status according to NYHA class is worse in
patients with HF due to left ventricular systolic dysfunction and IGT than in patients with NGT.
(Folia Cardiol. 2006; 13: 307–311)
left ventricular diastolic function, impaired glucose tolerance, heart failure
Introduction
The influence of glucose metabolism on the
cardiovascular system has recently become a sub-
ject of intense study [1–4]. According to epidemio-
logical studies, impaired glucose tolerance (IGT) is,
like diabetes, related to an increased risk of cardio-
vascular disease, including heart failure (HF) [5–8].
Hyperglycaemia plays an important role in the de-
velopment and progression of micro- and macroan-
giopathy in diabetes mellitus. Diabetes is also an
independent risk factor for HF [9]. Over the years
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confirmation has been given of the existence of a dia-
betic cardiomyopathy, with impaired contractility le-
ading to congestive HF [10, 11]. It has been indicated
that impaired diastolic filling related to impaired dia-
stolic function is the first abnormality in the presen-
ce of normal systolic left ventricular function [12, 13].
According to new observations, the interrela-
tionships between diabetes and HF are more com-
plicated and multi-factorial [3]. Recent studies in-
dicate the presence of reciprocal interrelationships
between HF and diabetes. Patients with chronic HF
are at higher risk of developing type 2 diabetes
mellitus. Of the increasing number of HF failure
patients about 30% have diabetes [3, 11]. Mortality
in this group is higher in comparison to non-diabe-
tics and the HF is more advanced [14–16]. Less is
known about HF patients with other glucose meta-
bolism abnormalities.
Left ventricular diastolic dysfunction is one of
the markers of HF severity. A restrictive filling pat-
tern of the left ventricle (RFP) as assessed by echo-
cardiography is related to increased mortality and the
need for heart transplantation [17, 18]. The complex
mechanisms underlying diastolic dysfunction have
been closely investigated. We were unable to find an
analysis of the possible influence of IGT on diastolic
function indices in patients with HF and low left ven-
tricular ejection fraction (LVEF).
The aim of the study was to determine the
extent to which IGT influences left ventricular dia-
stolic function in patients with HF and low LVEF.
Material and methods
The study included 61 patients who had been
referred to the Department of Cardiology of the
University School of Medical Sciences, Poznań, for
evaluation of HF. These were consecutive patients
with a mean age of 50.5 ± 8.0 years (28–69 years)
with stable HF, NYHA class I–IV (mean 2.3 ± 0.8),
and LVEF below 45% (11–44%; mean 26.8 ± 8.2%).
Patients were excluded if they had had a recent
(< 3 months) myocardial infarction, unstable an-
gina or coronary revascularisation, or if they had
a history of pulmonary disease, severe renal insuf-
ficiency or other organ disorders which would
significantly alter their physical capacity. All the
patients were maintained on their current HF
therapy with stable doses for at least two weeks
before the study. Fifty six (92%) patients rece-
ived angiotensin-converting enzyme inhibitors,
45 (74%) received furosemid, 45 (74%) beta-bloc-
kers, 34 (56%) digoxin and 27 (44%) spironolac-
tone.
M-mode, two dimensional and Doppler echo-
cardiography were performed in all patients with
a Hewlett-Packard Sonos 5500 echocardiographic
device and a 2.5/3.5 MHz transducer. Left ventri-
cular volumes: end-diastolic (LVEDV) and end-sy-
stolic (LVESV), and LVEF were measured from the
apical four-chamber view using a modified Simp-
son’s rule algorithm. Mitral inflow was measured
from the apical four-chamber view with a sample
volume positioned between the tips of the mitral
leaflets to derive the following variables: peak ear-
ly (E) and late (A) transmitral filling velocities, E/A
ratio and the deceleration time of the E wave (DTE).
A placing sample volume to record simultaneously
mitral and aortic flow isovolumetric relaxation time
(IVRT) was measured.
Restrictive filling pattern was defined either by
E/A ratio > 2 or E/A ratio between 1 and 2 with
DTE £ 130 ms.
The oral glucose tolerance test (OGTT) was
performed in all patients based on routine methods
used in the laboratory of SPSK No. 1 Hospital, Po-
znań. IGT was diagnosed with a fasting glucose le-
vel < 6.1 mmol/l and a level of 7.8 to 11.1 mmol/l
two hours after the glucose load [19].
The results are given as a mean and standard
deviation and proportions (%). The Mann-Whitney
and chi-square analyses were used to evaluate the
significance of differences between the groups. To
determine correlations between variables the Spe-
arman rank test was used. A multivariate regres-
sion analysis was performed to determine the rela-
tionship of E/A with NYHA class, furosemid dose
and LVEF. Furthermore, a multivariate regression
analysis was performed to determine the relation-
ship between NYHA class and parameters signifi-
cantly related in univariate analysis. A p value of
< 0.05 was taken to be statistically significant. The
statistical software Statistica 5.0 was used for all
analyses.
Results
Twenty five (41%) patients had IGT and
36 (59%) had normal glucose tolerance (NGT). The
clinical characteristics of both groups are presen-
ted in Table 1. There were no significant differen-
ces between the groups in age, body mass index
(BMI), duration of HF symptoms, creatinine level,
furosemid dose, treatment and proportion of ischa-
emic cardiomyopathy or hypertension. However, in
the patients with IGT the HF symptoms were more
severe as indicated by a higher NYHA class (there
was a significantly greater proportion of NYHA III
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and IV patients). There were no significant diffe-
rences in LVEDV and LVESV or in LVEF. There
was a trend toward a higher E/A and a shorter IVRT
in patients with IGT in comparison with NGT pa-
tients. RFP was significantly more frequent in pa-
tients with IGT than in those with NGT (60 vs. 33%;
p < 0.039) (Fig. 1). In the group of patients as
a whole there were significant correlations between
DTE and NYHA class (r = –0.28; p = 0.03) and
LVEF (r = 0.3; p = 0.02), and there was a trend
between DTE and glucose levels two hours after glu-
cose load (r = 0.28; p = 0.056) (Table 2). There were
also significant correlations between E/A and NYHA
class (r = 0.35; p = 0.03) and furosemid dose
Table 1. Clinical characteristics of patients with impaired glucose tolerance (IGT) and normal glucose
tolerance (NGT)
  IGT (n = 25) NGT (n = 36) p
Age (years) 51.6 ± 9.4 49.7 ± 6.9 NS
Body mass index [kg/m²] 29.0 ± 5.0 26.9 ± 5.3 0.1
Heart rate [1/min] 75 ± 14.6 76 ± 11 Ns
NYHA class 2.6 ± 0.6 2.1 ± 0.8 0.01
NYHA III + IV (%) 15 (60%) 10 (28%) 0.01
Creatinine [µmol/l] 90.1 ± 21 84.4 ± 16 NS
Furosemid dose [mg] 81.9 ± 45 66.7 ± 33 NS
Ischaemic heart disease (%) 12 (48%) 12 (33%) NS
Hypertension (%) 15 (60%) 18 (50%) NS
ACE inhibitors (%) 22 (88%) 34 (94%) NS
Beta-adrenolytics (%) 20 (80%) 25 (69%) NS
Furosemid (%) 21 (84%) 24 (67%) NS
Left ventricular ejection fraction (%) 26.7 ± 8.6 26.9 ± 8.0 NS
Left ventricular end-diastolic volumes [ml] 194 ± 88 197 ± 100 NS
Left ventricular end-systolic volumes [ml] 256.2 ± 105.4 262 ± 113 Ns
E [cm/s] 84.3 ± 23.9 76.7 ± 25 NS
Deceleration time of the E wave [ms] 153.7 ± 74 173 ± 60 NS
A [cm/s] 58.0 ± 31 71.0 ± 21 NS
E/A ratio 2.1 ± 1.5 1.2 ± 0.9 0.075
Isovolumetric relaxation time [ms] 68.0 ± 34 80.0 ± 31 0.084
0%
10%
20%
30%
40%
50%
60%
70%
Impaired glucose tolerance Normal glucose tolerance
RFP Non RFP
Figure 1. Restrictive filling pattern (RFP) in relation to
glucose metabolism abnormalities (p = 0.039).
Table 2. The relation of indices of left ventricular
diastolic function: E/A ratio and DTE and NYHA
functional class to the studied parameters in the
whole group of patients with heart failure
E/A DTE NYHA
Age NS NS p = 0.02
BMI NS NS NS
NYHA p = 0.03 p = 0.03 —
Furosemid p = 0.03 p = 0.08 p = 0.05
dose
HR NS p = 0.03 NS
Creatinine NS NS p = 0.06
Glucose 2 h p = 0.056 p = 0.09 p = 0.00005
post load
LVEF NS p = 0.02 p = 0.00003
LVESV NS p = 0.09 p = 0.002
LVEDV NS NS p = 0.02
DTE — deceleration time of the E wave, BMI — body mass index,
HR — heart rate, LVEF — left ventricular ejection fraction, LVESV — left
ventricular end-systolic volumes, LVEDV — left ventricular end-diastolic
volumes
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(r = 0.37; p = 0.03), and there was a trend between
E/A and glucose levels two hours after glucose load
(r = 0.28; p = 0.056) (Table 2). In a multivariate re-
gression analysis glucose level two hours after glu-
cose load in OGTT was related to E/A (p = 0.003)
independently of NYHA class (p = NS), diuretic dose
(p = 0.08) and LVEF (p = NS). In Table 2 the results
of correlations between NYHA class and clinical and
echocardiographic parameters are presented. In
a multivariate regression analysis performed with
the inclusion of parameters significantly related to
NYHA class in univariate analysis, glucose level two
hours after glucose load in OGTT was independen-
tly related to NYHA class (p = 0.01).
Discussion
The main finding of the study is that patients
with HF with low LVEF and IGT have more advan-
ced left ventricular diastolic dysfunction and a lo-
wer functional capacity, assessed as a higher NYHA
class, in comparison with patients without glucose
metabolism abnormalities.
It has recently been reported that glucose
metabolism abnormalities, not only associated with
diabetes but also with IGT or impaired fasting glu-
cose, are related to an increased risk of cardiova-
scular morbidity (CVD) [5, 6] and CVD mortality,
an increased risk of death due to ischaemic heart
disease, stroke and total mortality [7]. It has been
demonstrated that glucose serum level is a conti-
nuous variable without definite cut-off value with
reference to the risk of CVD [1]. Recent studies
have revealed new data on the mechanisms of the
action of hyperglycaemia on the structure and func-
tion of the cardiovascular system [1, 2]. The main
factors responsible for the observed abnormalities
are: endothelial dysfunction, increase in glycation
and glycosilation product levels, changes in coagu-
lation, an increase in oxidative stress, inflammation
and apoptosis. It seems that IGT and post-prandial
hyperglycaemia play an important role in the deve-
lopment and progression of atherosclerosis and are
significant risk factors of cardiovascular disease.
Diabetes is a disease of slow development. Vascu-
lar abnormalities in patients with type 2 diabetes
are usually diagnosed at the same time as the dia-
betes. It could be that vascular disease appears be-
fore diabetes is diagnosed at the IGT stage of pre-
ceding glucose metabolism abnormality [6].
In one recent study it was shown by means of
myocardial Doppler echocardiography that isolated
type 2 diabetes mellitus causes myocardial dysfunc-
tion that becomes worse in the presence of cardio-
vascular disease [20]. Less is known about myocar-
dial function in patients with IGT.
It has been documented that endothelial dys-
function, activation of an inflammatory process,
oxidative stress and apoptosis also have important
roles in the progression of HF symptoms [21]. It
has been suggested that insulin resistance (which
is associated with diabetes mellitus and IGT) in the
pathogenesis of HF has a part to play [21]. In this
study we have found that IGT worsens left ventri-
cular diastolic function in patients with HF and that
glucose level two hours after glucose load in the
OGTT is independently related to E/A. It seems
that more advanced diastolic dysfunction in patients
with HF and IGT may be due, as with diabetes, to
increased myocardial collagen accumulation and fi-
brosis with an increase in myocardial stiffness [22].
Increased glucose levels may lead to an intensifica-
tion of endothelial dysfunction, a decrease in nitric
oxide production and an increase in the production of
free radicals, leading to microangiopathy and myocar-
dial perfusion abnormalities and, further, to an incre-
ase in diastolic dysfunction. Diastolic dysfunction is
often observed in patients with HF. The most advan-
ced form, namely restriction, is associated with a lo-
wer exercise capacity and a worse prognosis [18, 23].
Impairment of diastolic function is due to increased
filling pressure of the left ventricle, which is related
to its increased stiffness. Diastolic function is depen-
dent on, among other factors, histological changes
related to collagen accumulation and an active rela-
xation process during the isovolumetric time. Under-
standing the processes influencing diastolic function
would seem important as, theoretically, an improve-
ment in diastolic properties may bring about an im-
provement in functional status and HF symptoms.
Patients with IGT have more advanced HF
symptoms, as indicated by the higher NYHA class.
As stated before, the severe diastolic dysfunction
(RFP) which was observed in most of these patients
is associated with a lower exercise capacity [23].
In a univariate analysis there were significant cor-
relations between NYHA class and diastolic func-
tion indices. However, in a multivariate regression
analysis glucose level two hours following glucose
load in an OGTT was related independently to
NYHA class. The decreased exercise capacity in
patients with IGT in comparison with patients with
NGT as evaluated according to NYHA class is pro-
bably due to higher vascular resistance as a conse-
quence of endothelial dysfunction and perhaps to
more pronounced skeletal muscle myopathy [21, 24].
It is proposed that OGTT be included in risk
stratification in patients with known ischaemic
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heart disease [25]. This may also be of value in pa-
tients with HF. From the clinical point of view ob-
servations regarding relations between IGT, diasto-
lic dysfunction and functional status in patients with
HF would appear important and may have some cli-
nical implications. It may be supposed that this gro-
up of patients has an opportunity to achieve the
greatest benefit from rehabilitation and physical
training, both of which have recently been recom-
mended for patients with heart failure.
Conclusion
In patients with heart failure and left ventricu-
lar systolic dysfunction with impaired glucose to-
lerance left ventricular diastolic dysfunction is more
advanced and the functional status worse, as
expressed by a higher NYHA class, in comparison
with patients with normal glucose tolerance.
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